The purpose of this study is to determine the effect of triple combination therapy with an anti-integrin [vedolizumab intravenous (IV)], a tumor necrosis factor (TNF) antagonist [adalimumab subcutaneously (SC)], and an immunomodulator (oral methotrexate) on endoscopic remission in participants with newly-diagnosed Crohn's disease stratified at higher risk for complications.